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Dipeptide tyrosyl-leucine exhibits 
antidepressant-like activity in mice
takafumi Mizushige1,2,3, Tomoki Uchida1 & Kousaku ohinata1*
Depression is a worldwide health problem. In the present study, we found that a dipeptide, tyrosyl 
leucine (Tyr-Leu, YL), administered orally, intracerebroventricularly, or intraperitoneally exhibited 
a potent antidepressant-like activity in the forced swim and tail suspension tests in naïve mice. YL 
increased the amount of cells expressing c-Fos, a marker for neuronal activity, in the dentate gyrus of 
the hippocampus. YL increased bromo-2′-deoxyuridine-positive cells and doublecortin expression in 
the dentate gyrus of the hippocampus, suggesting that YL enhanced the proliferation of hippocampal 
progenitor cells in vivo and in vitro. YL did not affect hippocampal mRNA and protein expression of 
BDNF, which is a regulatory factor of both neurogenesis and depression-like behavior. Intriguingly, 
YL suppressed activation of the hypothalamo-pituitary-adrenal axis by forced swim stress. Moreover, 
other aromatic amino acid-leucines, Phe-Leu and Trp-Leu, also exhibited antidepressant-like activities, 
suggesting that the structure of aromatic amino acid-leucine may be important for antidepressant 
activity. In addition, bovine milk casein-derived peptide, Tyr-Leu-Gly (YLG), an anxiolytic peptide, 
exhibited an antidepressant-like activity. Our findings demonstrate that YL exhibits an antidepressant-
like effect, moderates the stress response, and induces hippocampal neuronal proliferation through a 
signal pathway independent of BDnf.
A number of bioactive peptides have been found in enzymatic digests of various food proteins, and some of 
these peptides are known to act on the nervous system. We also reported that bioactive peptides derived from 
food proteins exhibit anxiolytic-like effects1–7, suggesting interactions between food components and the nerv-
ous system. Clarification of these interactions is challenging, since the food components, including food protein 
digests, consist of numerous molecular species. On the other hand, we have found novel bioactive peptides based 
on the structure-activity relationships of dipeptides. Thus, the discovery of dipeptides with potent activities and 
the their structure-activity relationships are very important and powerful clues to find novel peptides. Indeed, 
we initially found that a dipeptide, tyrosyl leucine (Tyr-Leu, YL), had a potent anxiolytic-like effect, comparable 
to that of diazepam, one of the general anxiolytics, in mice1. Thereafter, based on the structure rule required for 
the anxiolytic activity of YL, novel food-derived peptides have been rapidly been identified. Thus, we focused on 
dipeptides.
Major depressive disorder, one of the most common psychiatric diseases, is characterized by dysregulation of 
emotion and mood as well as abnormalities of cognitive function, sleep, appetite, and metabolism. It is known to 
be a leading cause of disability worldwide8,9. Anxiolytic molecules often exhibit antidepressant-like effects. Thus, 
in the current study, we investigated whether YL exhibits antidepressant-like activities using two behavioral tests 
commonly used to screen antidepressants, the forced swim and tail suspension tests.
Some antidepressant drugs were reported to promote hippocampal neurogenesis. It is known that unpredicta-
ble mild stress decreases the neural activity of hippocampal cells and the proliferation of hippocampal progenitor 
cells, and that these activities can be increased by the administration of antidepressants10–12. We then examined 
the hippocampal c-Fos protein-positive cells, known as a general neural activity marker13–15, and the effects of 
the proliferation of progenitor cells in vivo and in vitro. Brain-derived neurotrophic factor (BDNF) is known to 
induce the proliferation of hippocampal progenitor cells and has an antidepressant-like effect16–18. We also exam-
ined the expression of BDNF after administration of YL.
The hypothalamo-pituitary-adrenal (HPA) axis is neuroendocrine response to stressors and releases 
corticotropin-releasing hormone (CRH) and corticosterone19. Excess stress and impairment of the HPA axis 
system induce depressive behaviour and inhibit proliferation of neural stem cell. It has been reported that 
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some antidepressants improved this abnormal stress response20,21. Thus, we investigated whether YL inhibited 
stress-induced HPA axis activation by evaluating hypothalamic CRH expression and plasma corticosterone levels.
Mediators of YL-induced antidepressant-like effects were also investigated. We previously revealed that a 
novel signaling pathway with serotonin 5-HT1A receptor activation followed by the activation of dopamine D1 and 
GABAA receptors mediate antidepressant-like and anxiolytic-like activities1,6. We also found that this signaling 
pathway mediates the anxiolytic effect of YL. Thus, we tested whether the antidepressant-like activity of YL is also 
mediated by this common pathway.
In addition, we investigated the structure rules required for the antidepressant-like effect using YL analogues. 
We also tested the antidepressant-like effect of tyrosyl leucyl glycine (Tyr-Leu-Gly, YLG), a tripeptide found to 
be a potent anxiolytic peptide that is released after pepsin-pancreatic digestion, mimicking the gastrointestinal 
enzymatic conditions of αS1-casein, a major bovine milk protein22.
In this study, we investigated the effect of YL on antidepressant-like behaviour and its mechanisms. 
Neuronal cell proliferation in the hippocampus in vivo and in vitro, BDNF and HPA-related factors, and medi-
ators of YL-induced antidepressant-like effect were investigated biochemically and pharmacologically. The 
structure-activity relationships of antidepressant-like activity were also examined.
Results
To investigate antidepressant-like effects, we performed the forced swim test (FST) and tail suspension test 
(TST), used for screening antidepressants, in mice. YL, a simple dipeptide composed of l-tyrosine and l-leucine, 
decreased immobility time after intraperitoneal (F(4, 50) = 7.256, p < 0.05, 1–30 mg/kg) and intracerebroven-
tricular (F(3, 32) = 6.457, p < 0.05, 0.3–1 nmol/mouse) administrations in the FST (Fig. 1a,b). These results sug-
gest that YL exhibits an antidepressant-like effect in the FST. YL was also orally active (F(2, 35) = 3.196, p < 0.05, 
Fig. 1c). The YL-induced antidepressant-like activity was comparable to that of conventional antidepressants 
such as imipramine and fluvoxamine (F(3, 36) = 11.163, p < 0.05, Fig. 1d). In the TST, another behavioral test, 





















































Figure 1. YL exhibits an antidepressant-like effect in mice. (a–c) Antidepressant-like effect of YL. YL ((a) 
0.1–30 mg/kg, i.p.; (b) 0.1–1.0 nmol/mouse, i.c.v.; (c) 30–100 mg/kg, p.o.) was administered to mice, and the 
immobility time during a 4-min forced swim test (FST) session was measured 30 min after administration 
(n = 11; n = 8–9; n = 18, respectively). (d) Antidepressant-like activity of YL was comparable to those 
of already-known antidepressants. Immobility time during a 4-min FST session was measured after the 
administration of YL, fluvoxamine, and imipramine (30 mg/kg, i.p.) in mice (n = 7–8). (e) Antidepressant-like 
effect of YL (10–30 mg/kg, i.p.) in the tail suspension test (TST) (n = 6).
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antidepressants in both the FST and TST. YL exhibited an antidepressant effect in two mouse strains, C57BL/6 N 
and ddY, in the FST (data not shown). Thus, we demonstrated that YL exhibits an antidepressant effect in two 
different paradigms in two different strains of mice. YL did not affect locomotor activity in the elevated plus maze 
and open field tests1.
It was reported that antidepressants enhance adult proliferation of progenitor cells in the dentate gyrus of the 
hippocampus in rodents11. Indeed, YL administration increased the amount of cells expressing the c-Fos protein, 
a marker of neuronal activity, in the dentate gyrus of the hippocampus (p < 0.05, Mann-Whitney U test, Fig. 2a,b). 
We then investigated whether YL stimulates neural cell proliferation in the hippocampus. YL increased bromo-
deoxyuridine (BrdU)-positive puncta in the mouse hippocampus (p < 0.05, Mann-Whitney U test, Fig. 2c,d), 
and this increase was prolific in the dentate gyrus, where the proliferation of hippocampal progenitor cells was 
reported11. YL also increased the immunostaining intensity of doublecortin (DCX), a marker of newly differen-
tiated neurons (p < 0.05, Mann-Whitney U test, Fig. 2e,f), in the hippocampus, where BrdU-positive cells were 
increased. These results suggest that YL promotes hippocampal cell proliferation and neuronal maturation in vivo.
Next, we examined the proliferation activity of hippocampal neural stem cells on YL in vitro. YL increased 
the number of BrdU and nestin-double positive cells in neural stem cell culture (Fig. 3a,b). Thus, YL may directly 
promote hippocampal cell proliferation.
We also tested involvement of BDNF in the antidepressant-like effect of YL. There were no changes in BDNF 
mRNA expression or protein levels after YL administration (Fig. 4a,b), suggesting that the effects on neuronal cell 
proliferation and the antidepressant-like effect were independent of the BDNF system.
Stress response was related to the regulation of depressive behavior. Excessive stress increases depression-like 
behavior. We then investigated whether YL suppresses the stress response induced by forced swim stress. Forced 
swim stress for 6 min increased the serum corticosterone concentration (F(4, 35) = 9.878, p < 0.05) and hypo-
thalamic CRH mRNA expression (p < 0.05, Mann-Whitney U test, Fig. 5a,b). YL administration decreased the 
serum corticosterone concentration and hypothalamic CRH mRNA expression in the stressed mice (Fig. 5a,b). 
These results suggested that YL suppressed the stress response of the HPA axis.
To investigate whether the YL-induced antidepressant-like effect is mediated via the activation of serotonin 
5-HT1A, dopamine D1, and GABAA receptors, which are well known to be involved in emotional behavior, we 
used antagonists specific for these receptors. The antidepressant-like activity of YL was blocked by WAY100135 
(F(3, 22) = 6.218, p < 0.05, Fig. 6a), SCH23390 (F(3, 22) = 5.489, p < 0.05, Fig. 6b), bicuculline, or flumazenil (F(5, 
54) = 4.438, p < 0.05, Fig. 6c), antagonists of 5-HT1A, dopamine D1, and GABA- and benzodiazepine-binding sites 
of GABAA receptors. YL had no affinities for these receptors1, suggesting that these neurotransmitters may be 
released in association with the YL-induced antidepressant-like effect.
Next, we examined structure-activity relationship of antidepressant activity of YL. Leu-Tyr (LY), a retro-
sequence dipeptide, and tyrosine and leucine, by themselves were ineffective, suggesting that the amino acid 
sequence is important for the antidepressant-like effect (F(4, 32) = 4.783, p < 0.05, Fig. 7a). We found previously 
that other aromatic amino acid-leucine dipeptides also exhibited anxiolytic activity. We examined depression-like 
activity of the peptides, Phe-Leu (FL) and Trp-Leu (WL). FL and WL were found to significantly decrease immo-
bility time in the FST (F(3, 29) = 5.786, p < 0.05, Fig. 7b). On the other hand, Leu-Phe (LF) and Leu-Trp (LW) 
had no effect on immobility time (data not shown). These results suggested that aromatic amino acid-leucine was 
involved in the antidepressant-like activity.
We investigated antidepressant-like effect of YLG, an bovine milk casein-derived tripeptide-including YL 
sequence reported as an anxiolytic peptide. We found that YLG administration decreased immobility time in the 
FST (F(4, 51) = 6.812, p < 0.05, Fig. 7c). The intensity of the activity of YLG was approximately the same as that of YL.
Discussion
We found that a dipeptide, YL, exhibits a potent antidepressant-like effect after peripheral administration in 
behavioral tests, comparable to that of antidepressants, imipramine and fluvoxamine. In addition, centrally 
administered YL exhibited an antidepressant-like effect. Although endogenous peptide hormones, such as leptin, 
ghrelin, insulin, and peptide YY, cross the blood-brain barrier (BBB)23, it is not clear whether YL crosses the 
BBB; however, brain-transportable dipeptides have recently been reported24. Thus, it cannot be ruled out that 
YL reaches the brain in dipeptide-form and act on the central nervous system (CNS). Further investigations are 
needed to clarify whether YL crosses the BBB and the mechanism of its antidepressant-like effects.
We found that YL administration increased BrdU-positive cells in the hippocampus of mice. Additionally, 
YL increased BrdU-positive cells in cultured hippocampal neural stem cells. Thus, we confirmed that YL directly 
promoted the proliferation of hippocampal progenitor cells. It was reported that hippocampal neuronal prolif-
eration observed in adults decreases in patients with depression, and that enhancement of the proliferation of 
hippocampal progenitor cells contributes to improvements seen after treatment with antidepressants25–28. These 
results suggest that YL mimics antidepressants to enhance neuronal proliferation.
BDNF is known to mediate the proliferation of hippocampal progenitor cells and a fast-acting 
antidepressant-like effect induced by ketamine, an antagonist of glutamate N-methyl-D-aspartate (NMDA) 
receptors29,30. It was also reported that the BDNF-mediated antidepressant-like effect was independent of the 
HPA axis31, which is activated by stress.
In contrast, YL, which acts independently of BDNF, suppressed the stress-induced activation of the HPA axis. 
As HPA axis activation is also reported to suppress the proliferation of hippocampal progenitor cells31–35, the pos-
sibility that YL-induced suppression of HPA axis activation in response to stress contributes to the proliferation 
of hippocampal progenitor cells in vivo cannot be ruled out. In addition, our study found neuronal proliferation 
after acute administration of YL, but further studies are necessary to clarify whether YL induces neuronal dif-
ferentiation and maturation after acute and chronic treatments, and whether YL modulates the BDNF system 
following long-term administration and/or in depression model mice.
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The antidepressant-like effect of YL was blocked by antagonists of 5-HT1A, dopamine D1, and GABAA receptors. 
It was reported that 5-HT1A and dopamine D1 receptors in the hippocampus are involved in the antidepressant-like 
effect and hippocampal cell proliferation28,36,37. In the future, it will be necessary to elucidate how the monoamine 





























































Figure 2. YL activates hippocampal cells and exhibits cell proliferation in the hippocampal dentate gyrus in 
vivo. (a,b) Immunostaining of the c-Fos protein. Hippocampal neuronal activity was evaluated by counting 
c-Fos-positive cells (n = 4). Scale bar, 100 μm. Values are expressed as the mean ± S.E.M. *P < 0.05 compared 
with each group by nonparametric Mann–Whitney U test. (c,d) Co-immunofluorescence staining of BrdU (red) 
and DAPI (blue). Hippocampal neuronal cell proliferation was evaluated by counting BrdU-positive cells in the 
whole hippocampus and dentate gyrus (n = 4). Values are expressed as the mean ± S.E.M. *P < 0.05 compared 
with each group by nonparametric Mann–Whitney U test. Scale bar, 100 μm. (e,f) Immunofluorescence 
staining of Dcx (green). Hippocampal neural maturation was evaluated by immunofluorescence intensity using 
Image J software (n = 4). Scale bar, 100 μm. Values are expressed as the mean ± S.E.M. *P < 0.05 compared with 
each group by nonparametric Mann–Whitney U test.
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A number of bioactive peptides have been isolated from digests of various food proteins. We previously pre-
dicted that there are anxiolytic-like peptides released by proteases present in the gastrointestinal tract, based on 
structure-activity relationship information1,8,38. We found that YLG was released after digestion by gastrointesti-
nal proteases mimicking physiological conditions, and produce a potent anxiolytic-like effect via the activation of 
5-HT1A, dopamine D1 and GABAA receptors8. In addition, YLG improved a decline in cognition and a reduction 
in neural stem cell proliferation in mice on a high-fat diet39. These findings raise the possibility that bioactive 
peptides, including YLG, derived from food proteins potentially affect emotional behaviors via the activation of 
5-HT1A, dopamine D1 and GABAA receptors after a meal.
Similarly to YL, other aromatic amino acid-leucine dipeptides, FL and WL, also had antidepressant-like effects. 





























Figure 3. YL promotes proliferation of hippocampal neural stem cell in vitro. (a,b) Co-immunofluorescence 
staining of BrdU (red), nestin (green), and DAPI (blue). Hippocampal neural stem cell proliferation 
was evaluated by counting BrdU and nestin-positive cells in the culture (n = 4). Values are expressed as 
the mean ± S.E.M. Different characters represent significant differences (P < 0.05) among groups by the 
nonparametric Mann–Whitney U test. Scale bar, 100 μm.
Figure 4. YL does not activate BDNF systems. (a) Hippocampal BDNF mRNA expression normalized to 
β-actin 30 min after i.p. administration of YL (30 mg/kg, n = 7). (b) Changes in hippocampal BDNF protein 
levels after YL administration (30 mg/kg, i.p., n = 7). Values are expressed as the mean ± S.E.M. *P < 0.05 
compared with each group by ANOVA followed by Tukey-Kramer’s test.
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for the antidepressant-like effect. This structure-activity relationship of dipeptides in antidepressant-like activ-
ity is similar to that in anxiolytic-like activity, which we previously reported1,38. Furthermore, tripeptides with 
a YL sequence at the N-terminus, including YLQ and YLY, exhibited antidepressant-like effects, whereas LYL 
was ineffective (data not shown), suggesting that the YL sequence at the N-terminus is necessary for the potent 
antidepressant-like effects, and that C-terminal elongation of YL may not inhibit an antidepressant-like effect.
In summary, the dipeptide YL and the tripeptide YLG exhibited antidepressant-like effects in behavioral tests 
in mice after central and peripheral administration. These activities were orally active. YL promoted the prolif-
eration of hippocampal progenitor cells independently of the BDNF pathway, and inhibited stress responses in 
the HPA axis.
Figure 5. (a) Plasma corticosterone levels with and without the FST 30 min after i.p. administration of YL 
(3–30 mg/kg, n = 11–12). (b) Hypothalamic CRH mRNA expression normalized to β-actin with and without 
the FST after i.p. administration of YL (30 mg/kg, n = 4). Values are expressed as the mean ± S.E.M. *P < 0.05 
compared with each group by ANOVA followed by Tukey-Kramer’s (a) or nonparametric Mann–Whitney U (b) 
tests.
Figure 6. YL activates the 5-HT1A, dopamine D1, and GABAA systems. Effect of serotonin 5-HT1A, dopamine 
D1, and GABAA antagonist on YL-induced antidepressant-like activity. WAY100135 dihydrochloride, a 
serotonin 5-HT1A receptor antagonist (10 mg/kg), R(+)-SCH-23390 hydrochloride, a dopamine D1 receptor 
antagonist (30 mg/kg), or (−)-bicuculline (5 mg/kg) or flumazenil, antagonists of GABA- and benzodiazepine-
binding sites of GABAA receptors, respectively (1 mg/kg), was co-administered once intraperitoneally with the 
peptide 30 min before FST. Values are expressed as the mean ± S.E.M. (n = 9–10). Different characters represent 
significant differences (P < 0.05) among each group by ANOVA followed by Tukey-Kramer’s test.
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Methods
Animals. Male ddY mice (24–27 g; SLC, Shizuoka, Japan) were reared in plastic cages in a room controlled 
with a 12-hour light-dark cycle (dark phase: 19:00–7:00), constant temperature (23 ± 1 °C), and constant humid-
ity (55 ± 5%). The mice were housed for more than 3 days for acclimatization to the environment. They were 
fed regular tap water and a commercial solid diet (MF; Oriental Yeast, Osaka, Japan) ad libitum. All animal 
experiments were performed in accordance with the guideline of Kyoto University Ethics Committee for Animal 
Research Use. All animals were euthanized by an overdose of anesthesic or cervical spine dislocation after the 
experiment. This study was approved by Kyoto University Ethics Committee for Animal Research Use (approval 
number, 26–53).
Reagents. Tyr-Leu (YL), Phe-Leu (FL), Trp-Leu (WL), Leu-Tyr (LY), Leu-Phe (LF), and Leu-Trp (LW) were 
purchased from Bachem AG (Bufendorf, Switzerland). Tyr-Leu-Gly (YLG) was synthesized by the Fmoc strat-
egy, and purified by reverse-phase HPLC. Amino acids Tyr, Leu, Phe, and Trp were obtained from Wako Pure 
Chemical Industries, Ltd. (Osaka, Japan). WAY100135 dihydrochloride, a serotonin 5-HT1A receptor antagonist; 
R(+)-SCH-23390 hydrochloride, a dopamine D1 receptor antagonist; and (−)-bicuculline methochloride and 
Flumazenil, γ-aminobutyric acid (GABA)A receptor antagonists, were purchased from Tocris Bioscience (Bristol, 
UK).
forced swim test. The forced swim test (FST) was performed as previously described40. The total immo-
bility time of mice was assessed according to Porsolt et al.41. Briefly, mice were individually forced to swim in an 
open cylindrical container (diameter 10 cm, height 20 cm), containing 10 cm of water at 25 ± 1 °C. The forced 
swim test was performed during the light phase of the light/dark cycle. The total immobility time (s) was meas-
ured using the SUPERMEX system (Muromachi Kikai Co., Ltd., Tokyo, Japan) in a time span of 2–6 min. Mice 
were considered immobile when they made no attempts to escape by movements to keep their heads above the 
water. A decrease in the immobility time was set as an indicator of an antidepressant-like effect. Previous studies 
Figure 7. Antidepressant-like activity of the structure-activity relationship of YL. (a) Immobility time during 
a 4-min FST session when YL, LY, Y, and L (30 mg/kg body weight) were administered intraperitoneally to 
mice (n = 7–8). Value are expressed as the means ± S.E.M. Asterisks show significant differences between 
the YL-administered group and the vehicle-administered group. *P < 0.05 as determined by ANOVA. (b) 
Structure-activity relationship of the antidepressant-like effect of YL in the FST. YL, FL, and WL (30 mg/kg, i.p.) 
were administered to mice and immobility time during a 4-min FST session was measured (n = 7–8). (c) YLG 
(10–100 mg/kg, i.p.) and YL (30 mg/kg, i.p.) were administered to mice, and immobility time during a 4-min 
FST session was measured 30 min after administration (n = 7–8).
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showed that dipeptide and tripeptide affected brain functions, producing depressive, anxiety, and cognitive effects 
30 min after peptide administration1,8,38–40,42. FST was started 30 min after administration of the peptide or saline 
orally, intracerebroventricularly, or intraperitoneally. WAY100135 dihydrochloride (10 mg/kg), R(+)-SCH-23390 
hydrochloride (30 μg/kg), (−)-bicuculline methochloride (5 mg/kg), or Flumazenil (1 mg/kg) was coadminis-
tered i.p. once with the peptide 30 min prior to the behavioral test. Peptides and antagonists were dissolved in 
saline.
tail suspension test. Tail suspension test (TST) was performed as previously described39. The total dura-
tion of immobility induced by tail suspension was measured according to the method described by Steru et al.43. 
Briefly, mice were suspended 30 cm above the floor using adhesive tape placed approximately 1 cm from the tip of 
the tail. Immobility time was recorded during 2 to 6 min periods.
c-fos labeling. Synthesis of the c-Fos protein required 30 min of neuronal activity44. Control mice were 
administered the peptide sample or vehicle. Mouse brains were removed 1 h later. For immunohistochemistry, 
brains were fixed with 4% PFA and then immunostained with anti-c-Fos (1:1000; rabbit-IgG; Merck Millipore, 
Bedford, MA, USA) and biotin conjugated anti-rabbit IgG (1:1000, Jackson ImmunoReseach Inc., West Grove, 
PA, USA) antibodies. C-Fos-labeled cells were counted in the hippocampus under a microscope (Olympus, 
Tokyo, Japan).
Hippocampal cell proliferation assay with BrdU in vivo. BrdU (Sigma, St. Louis, MO, USA) and pep-
tide samples were dissolved in saline. Mice received i.p. administration of the peptide sample or vehicle 30 min 
before BrdU administration. Then, mice were administered BrdU (100 mg/kg; i.p.) to label proliferating cells in 
the hippocampus, and brains were removed 24 h later. For immunohistochemistry, brains were fixed with 4% PFA 
and then immunostained with anti-nestin (1:200; mouse-IgG; Chemicon, Temecula, CA, USA) and anti-BrdU 
(1:200; rat-IgG; Abcam Inc., Cambridge, MA, USA) antibodies, and DAPI. Alexa 488 conjugated anti-mouse and 
alexa 594 conjugated anti-rat (1:1000; Thermo Fisher Scientific Inc., San Jose, CA, USA) were used as secondary 
antibodies. BrdU-labeled cells were counted in the hippocampus under a microscope (Olympus).
Hippocampal neural maturation assay with Dcx in vivo. Mice received i.p. administration of YL or 
vehicle, then brains were removed 24 hours later. For immunohistochemistry, brains were fixed with 4% PFA and 
then immunostained with an anti-doublecortin (Dcx) (1:1000; rabbit-IgG; Abcam) antibody. Alexa 488 conju-
gated anti-rabbit (1:1000; Thermo Fisher Scientific Inc.) was used as the secondary antibody. Dcx immunostain-
ing intensity was measured using Image J software.
neuronal proliferation assay with BrdU in vitro. Neural progenitor cells were isolated from ddY mice 
at P1. The hippocampus was dissected free of the meninges and enzymatically digested with 0.25% trypsin-EDTA 
(Invitrogen) for 5 min at 37 °C, followed by washing with a 0.1% w/v trypsin inhibitor, aprotinin (Sigma). A 
single-cell suspension was plated in a 12-well culture plate. The culture medium was composed of DMEM/Ham’s 
F12 (1:1; Sigma), B27 supplement (Invitrogen), GlutaMAX supplement (Invitrogen), penicillin-streptomycin 
solution (Invitrogen), 10 ng/ml basic fibroblast growth factor (bFGF; Pepro Tech, Rocky Hill, NJ, USA), and 
20 ng/ml epidermal growth factor (EGF; Pepro Tech). Neural progenitor cells were grown as free-floating neuro-
spheres for 7 days in a 5% CO2, 95% air humidified atmosphere. Neurospheres were collected and then digested 
with 0.25% trypsin-EDTA for 5 min at 37 °C, followed by washing with 0.1% w/v trypsin inhibitor. Digested cells 
were plated on poly-l-ornithine- and fibronectin-coated 8-well culture dishes in serum-free neurobasal (NB) 
medium (Invitrogen) containing B27 supplement, GlutaMAX supplement, penicillin-streptomycin solution, 
10 ng/ml bFGF, and 20 ng/ml EGF, and cultured for 3 days until used in the neuronal proliferation assay with 
BrdU.
Peptide or PBS was added in NB medium containing B27 supplement. After the addition of the peptide, cells 
were incubated in NB medium containing B27 supplement and 20 μM BrdU for 24 h. For immunocytochemistry, 
cultured cells were fixed with 4% PFA and then immunostained with anti-nestin (1:200; mouse-IgG; Chemicon) 
and anti-BrdU (1:200; rat-IgG; Abcam) antibodies, and DAPI. Alexa 488 conjugated anti-mouse and alexa 594 
conjugated anti-rat (1:1000; Thermo Fisher Scientific Inc., San Jose, CA, USA) were used as secondary antibodies.
Real-time Rt-pcR. Hippocampal BDNF and hypothalamic CRH mRNA expression levels were measured 
using real-time RT-PCR. Control mouse hippocampus and hypothalamus was excised 30 min after i.p. adminis-
tration of YL and was kept in RNAlater RNA Stabilization Reagent (QIAGEN Sciences Inc., Germantown, MD, 
USA) after decapitation under deep anesthesia until RNA extraction. Total RNA was extracted from the hip-
pocampus using the RNeasy Lipid Tissue Kit (QIAGEN Sciences Inc.) and transcribed to cDNA with random 
primers using Takara PrimeScript® RT Master Mix (Takara, Osaka, Japan). For quantitative PCR, we ampli-
fied the cDNA using the Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) 
with Platinum SYBR Green qPCR SuperMix-UDG and ROX solution (Invitrogen) and each primer set specific 
for mouse BDNF and CRH, according to the manufacturer’s instructions. The following primers were used for 
real-time RT-PCR: forward bdnf: 5′-GCG GCA GAT AAA AAG ACT GC-3′, reverse bdnf: 5′-TCA GTT GGC 
CTT TGG ATA CC-3′, forward crh: 5′-GCA GTT AGC TCA GCA AGC TCA C-3′, reverse crh: 5′-CAA ATG 
ATA TCG GAG CTG CG-3′, forward β-actin: CTG CGC AAG TTA GGT TTT GTC A, reverse β-actin: TGC 
TTC TAG GCG GAC TCT TAC TG. The reactions were cycled 40 times with denaturation at 95 °C for 15 s, and 
with annealing and elongation at 60 °C for 30 s. The relative expression level of each mRNA was normalized 
against the mRNA expression level of β-actin.
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ELISA. Control mouse hippocampus was excised 15, 30, 60, 120 min, 24 h after i.p. administration of YL. 
Blood was collected 30 min after i.p. administration of YL. Hippocampal BDNF protein and plasma corticos-
terone levels were measured by ELISA. The hippocampus was recovered and homogenized with ice-cold NP40 
cell lysis buffer (Invitrogen). Blood was collected in a tube rinsed with heparin under deep anesthesia, then cen-
trifuged (1000 g × 10 min at 4 °C). BDNF levels of the protein extract were measured using the Promega BDNF 
Emax® ImmunoAssay System (Promega, Madison, WI, USA) according to the manufacturer’s instructions. 
Corticosterone levels in the plasma were measured using the Assaypro corticosterone ELISA kit (Assaypro Llc, 
Brooklyn, NY, USA) according to the manufacturer’s instructions.
Statistical analysis. All values are expressed as the means ± S.E.M. One-way analysis of variance (ANOVA) 
followed by Tukey-Kramer’s test was used to assess differences among three or more groups. Unpaired t-tests were 
used to assess differences between two groups. P values less than 0.05 were considered significant.
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